Across TCGA pan-cancer cohorts, IRF7 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IRF7 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IRF7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IRF7 expression acts as an unfavorable survival marker.

HNSC and UCEC are the cancer types where IRF7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.158	0.626	.013	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: IRF7 tumor-vs-normal RNA expression · all IRF7 data types